Daniel Shelly, PhDVice President Business Development and Alliances at Prescient Therapeutics
Daniel Shelly, Ph.D., MBA is Vice President of Business Development and Alliances at Prescient Therapeutics where he is responsible for advancing a next-generation, modular, and post-infusion controllable CAR-Immune cell therapy platform along with small molecule targeted therapies. Previously, he was Director of Global Business Development and Strategic Partnerships for the global non-profit PATH, where he was the Co-Lead for the COVID-19 task force. He has over 19 years of biopharmaceutical BD licensing and alliance management experience. He is also an adjunct professor in the Masters in Clinical Drug Development program at the University of Cincinnati’s College of Pharmacy.